<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02365779</url>
  </required_header>
  <id_info>
    <org_study_id>2014.875</org_study_id>
    <nct_id>NCT02365779</nct_id>
  </id_info>
  <brief_title>Optical Biopsy and Fallopian Tube</brief_title>
  <acronym>FALLOPTIC</acronym>
  <official_title>Dynamic Real-time in Vivo Confocal Laser Endomicroscopy Cellvizio® of the Fallopian Tube During Laparoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High-grade serous ovarian cancer is the most threatening type of gynaecological cancer with&#xD;
      an important mortality due to late diagnosis. However the prognosis is excellent in the early&#xD;
      stages of the disease. Recently it has been described a new serous carcinogenic sequence from&#xD;
      the fallopian tube with tubal precancerous lesions. Therefore the identification of these&#xD;
      early preinvasive lesions would be of great interest in the population with hereditary&#xD;
      predisposition for ovarian cancer (concept of oncofertility) and in the general population&#xD;
      (to determine whether bilateral salpingectomy has to be performed during a hysterectomy for&#xD;
      benign disease).&#xD;
&#xD;
      The optical biopsy has been developed and validated in the detection of early precancerous&#xD;
      lesions (such as Barrett's oesophagus or in situ cancer of the bladder). The first objective&#xD;
      of this study is to prospectively assess the efficacy of optical biopsy (Cellvizio®) in the&#xD;
      study of fallopian tubes during laparoscopy with correlation between the histopathological&#xD;
      and immunohistochemical analysis and the endomicroscopy image interpretation. The second&#xD;
      objective is to describe the optical biopsy pictures in order to state a classification.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion Criteria:&#xD;
&#xD;
        -  Woman aged 18 years or more&#xD;
&#xD;
        -  All patients with laparoscopic salpingectomy for benign conditions (tubal ligation,&#xD;
           during a hysterectomy), for prophylactic conditions (BRCA mutation) or in case of pelvic&#xD;
           cancers&#xD;
&#xD;
        -  Informed and signed consent&#xD;
&#xD;
      Exclusion Criteria:&#xD;
&#xD;
        -  Interview revealing disorder entailing unacceptable risk of postoperative complications:&#xD;
           coagulation disorder, immune system disorder, evolutive disease, etc.&#xD;
&#xD;
        -  Pregnancy, ongoing or planned during the study period&#xD;
&#xD;
        -  Allergy to fluorescein&#xD;
&#xD;
        -  Previous allergy or anaphylactic shock during an angiography&#xD;
&#xD;
        -  Allergic or hypersensibility reactions&#xD;
&#xD;
        -  Severe asthma, chronic cardiac or pulmonary diseases&#xD;
&#xD;
        -  Restricted renal function&#xD;
&#xD;
        -  Patient under a beta-blockers treatment&#xD;
&#xD;
        -  Inability to understand information provided&#xD;
&#xD;
        -  Not covered by a national health insurance scheme, prisoner or under administrative&#xD;
           supervision&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between the histopathological and immunohistochemical analysis and the endomicroscopy image interpretation</measure>
    <time_frame>DAY 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>: Description of the optical biopsy pictures in order to state a classification</measure>
    <time_frame>DAY 1</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Bilateral Laparoscopic Salpingectomy</condition>
  <arm_group>
    <arm_group_label>bilateral laparoscopic salpingectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bilateral laparoscopic salpingectomy</intervention_name>
    <description>Use of the confocal laser endomicroscopy Cellvizio® system during laparoscopy salpingectomy</description>
    <arm_group_label>bilateral laparoscopic salpingectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>endomicroscopy Cellvizio® system</intervention_name>
    <arm_group_label>bilateral laparoscopic salpingectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Woman aged 18 years or more&#xD;
&#xD;
          -  All patients with laparoscopic salpingectomy for benign conditions (tubal ligation,&#xD;
             during a hysterectomy), for prophylactic conditions (BRCA mutation) or in case of&#xD;
             pelvic cancers&#xD;
&#xD;
          -  Informed and signed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Interview revealing disorder entailing unacceptable risk of postoperative&#xD;
             complications: coagulation disorder, immune system disorder, evolutive disease, etc.&#xD;
&#xD;
          -  Pregnancy, ongoing or planned during the study period&#xD;
&#xD;
          -  Allergy to fluorescein&#xD;
&#xD;
          -  Previous allergy or anaphylactic shock during an angiography&#xD;
&#xD;
          -  Allergic or hypersensibility reactions&#xD;
&#xD;
          -  Severe asthma, chronic cardiac or pulmonary diseases&#xD;
&#xD;
          -  Restricted renal function&#xD;
&#xD;
          -  Patient under a beta-blockers treatment&#xD;
&#xD;
          -  Inability to understand information provided&#xD;
&#xD;
          -  Not covered by a national health insurance scheme, prisoner or under administrative&#xD;
             supervision&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Service de Gynécologie, Hôpital Femme Mère Enfant, Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>February 11, 2015</study_first_submitted>
  <study_first_submitted_qc>February 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <last_update_submitted>September 4, 2015</last_update_submitted>
  <last_update_submitted_qc>September 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>salpingectomy</keyword>
  <keyword>optical biopsy</keyword>
  <keyword>Cellvizio®</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

